Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)

Next Previous
Search
Trial Profile

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Serplulimab (Primary) ; Surufatinib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms SAGE

    • Most Recent Events

    • 13 Oct 2023 Planned primary completion date changed from 23 Oct 2023 to 31 Oct 2023.
    • 13 Oct 2023 Planned initiation date changed from 30 Aug 2023 to 23 Oct 2023.
    • 13 Oct 2023 The study protocol was amended as the interventional study model changed from single-group assignment to parallel assignment. Subjects will receive the sulfatinib and serplulimab in conjunction with albumin-paclitaxel and gemcitabine regimen. Furthermore, it compares the efficacy of sulfatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine to the albumin-paclitaxel and gemcitabine regimen. Number of treatment arms changed from 1 to 2 and number of pt changed to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top